Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 4, 2022

SAN DIEGO, July 19, 2022 (GLOBE NEWSWIRE) — Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2022 financial and operating results after the market closes on Thursday, August 4, 2022, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

To participate in the conference call by telephone, dial (877) 407-0890 or (201) 389-0918 and reference Maravai LifeSciences. The call will also be available via live or archived webcast on the “Investors” section of the Maravai web site at https://investors.maravai.com.

About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.

CONTACT: Contact Information:
Media Contact: Sara Michelmore
MacDougall Advisors
+1 781-235-3060
maravai@macdougall.bio 

Investor Contact: Deb Hart
Maravai LifeSciences
+ 1 858-988-5917
ir@maravai.com

Staff

Recent Posts

Bruno Vision Care Receives FDA Approval for Deseyne® Contact Lens with FusionTechnology™

Lenses feature novel hydrogel material with patented controlled-release technology Only lenses available in the world…

2 hours ago

Spectrum Vascular Welcomes New Executive Leadership

WHITE PLAINS, N.Y.--(BUSINESS WIRE)--Spectrum Vascular (“Spectrum” or the “Company”), a provider of vascular access and…

2 hours ago

Adia Nutrition Inc. Files for OTCQB Uplisting with OTC Markets, Emphasizing OTC-Handled 15c2-11 for Transparency and Investor Reach

Winter Park, Florida--(Newsfile Corp. - April 14, 2025) - Adia Nutrition Inc. (OTC Pink: ADIA),…

2 hours ago

Neural Therapeutics Strengthens IP Portfolio With a Patent Application

Treatment of Major DSM-5 Disorders, Including Addiction, Depression and Anxiety, With Sub-Hallucinogenic Mescaline DosesExtraction Technology…

2 hours ago

Free Oral Cancer Screenings in Honor of Oral, Head and Neck Cancer Awareness Month

26 USOSM Surgeon Partners to Participate Across Seven States IRVING, Texas, April 14, 2025 (GLOBE…

2 hours ago